Resiquimod (R-848)

Catalog No.S8133 Batch:S813301

Print

Technical Data

Formula

C17H22N4O2
Molecular Weight 314.38 CAS No. 144875-48-9
Solubility (25°C)* In vitro DMSO 63 mg/mL (200.39 mM)
Ethanol 21 mg/mL (66.79 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.
Targets
TLR7 [1] TLR8 [1]
In vitro

Resiquimod activates immune cells and induces proliferation of wild-type splenocytes via the Toll-like receptor 7 (TLR7)-MyD88-dependent signaling pathway. [1]

Resiquimod also modulates dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. [2]

Resiquimod induces the differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells, and may improve cancer immunotherapy by reducing immunosuppressive MDSCs. [3]
In vivo

In wild-type mice, Resiquimod (50 nmol, i.p.) induces increased serum concentrations of IFN-alpha, TNF-alpha and IL-12, while neither TLR7-deficient mice nor MyD88-deficient mice show an increase in these cytokines. [1]

In a murine model of allergic asthma, Resiquimod (i.n., 20 μg/mouse) reduces allergen induced airway reactivity and inflammation via reduction in Nrf2 signaling. [4]

Protocol (from reference)

Cell Assay:

[5]
  • Cell lines

    Peripheral blood leukocytes

  • Concentrations

    0.5–2 μg/ml

  • Incubation Time

    24 h

  • Method

    Cells were treated with various concentrations of drug.
Animal Study:

[1]
  • Animal Models

    Wild-type mice, TLR7-deficient mice, and MyD88-deficient mice

  • Dosages

    50 nmol

  • Administration

    i.p.

Selleck's Resiquimod (R-848) has been cited by 16 publications

Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer [ Int J Nanomedicine, 2024, 19:3589-3605] PubMed: 38645464
Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype [ Front Immunol, 2024, 15:1331480] PubMed: 38545103
Reduced Renal CSE/CBS/H2S Contributes to the Progress of Lupus Nephritis [ Biology (Basel), 2023, 12(2)318] PubMed: 36829595
Targetable leukemia dependency on noncanonical PI3Kγ signaling [ bioRxiv, 2023, 10.1101/2023.12.15.571909] PubMed: none
Drug-Dependent Morphological Transitions in Spherical and Worm-Like Polymeric Micelles Define Stability and Pharmacological Performance of Micellar Drugs [ Small, 2022, 18(4):e2103552] PubMed: 34841670
Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment [ Eur J Pharm Biopharm, 2022, S0939-6411(2200306-X)] PubMed: 36549400
Co-ordinated control of the ADP-heptose/ALPK1 signalling network by the E3 ligases TRAF6, TRAF2/c-IAP1 and LUBAC [ Biochem J, 2022, 479(20):2195-2216] PubMed: 36098982
Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2 [ Adv Mater, 2021, 33(51):e2104362] PubMed: 34651342
Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs [ Pharmaceutics, 2021, 13(3)365] PubMed: 33801967
Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2 [ bioRxiv, 2021, 2021.03.31.437792] PubMed: 33821276

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.